DarrenyYSM
2021-11-03
Good news for Pfizer.
Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":841538332,"tweetId":"841538332","gmtCreate":1635923546260,"gmtModify":1635923546386,"author":{"id":3586939965895816,"idStr":"3586939965895816","authorId":3586939965895816,"authorIdStr":"3586939965895816","name":"DarrenyYSM","avatar":"https://static.tigerbbs.com/7fb98b9b6cf4f7ff1919bf29b2d3c62f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good news for Pfizer.</p></body></html>","htmlText":"<html><head></head><body><p>Good news for Pfizer.</p></body></html>","text":"Good news for Pfizer.","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/841538332","repostId":1167449573,"repostType":4,"repost":{"id":"1167449573","kind":"news","pubTimestamp":1635922924,"share":"https://www.laohu8.com/m/news/1167449573?lang=zh_CN&edition=full","pubTime":"2021-11-03 15:02","market":"us","language":"en","title":"Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167449573","media":"The Wall Street Journal","summary":"Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales\nOf t","content":"<p>Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales</p><p><blockquote>Shot 130亿美元的收入为制药商第三季度销售额做出了最大贡献</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/85ed5523396f63a03a4597730fa17ed8\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>Of the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.</span></p><p><blockquote><p class=\"t-img-caption\"><span>在近2亿已完全接种疫苗的美国人中，超过一半的人接种了辉瑞疫苗。</span></p></blockquote></p><p> Pfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.</p><p><blockquote>辉瑞公司(Pfizer Inc.)将今年Covid-19疫苗的销售额预测上调至约360亿美元，增幅约7%，正值美国准备向2800万5至11岁儿童分发疫苗之际。</blockquote></p><p> The New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.</p><p><blockquote>这家总部位于纽约的制药商表示，其与合作伙伴BioNTech SE开发的疫苗的销售预测考虑了今年预计交付约23亿剂疫苗。这些公司已经提高了生产剂量的能力，并正在与海外其他公司合作生产剂量。</blockquote></p><p> The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.</p><p><blockquote>该疫苗130亿美元的收入是辉瑞第三季度约240亿美元销售额的最大贡献者，同比增长了一倍多。辉瑞首席执行官Albert Bourla在财报看涨期权上表示，今年超过75%的疫苗销售额来自国际销售，因为该疫苗已到达152个国家。</blockquote></p><p> The vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.</p><p><blockquote>在接受初始供应的国家和其他已经开始加强运动的国家，以及尚未接受任何供应的国家，该疫苗在全球范围内仍然有需求。美国已授权为许多高危成年人额外注射该疫苗，并于上周批准将该疫苗用于5岁以下的儿童。</blockquote></p><p> In the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency’s endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.</p><p><blockquote>在美国，该疫苗预计最早将于周三在一些地方提供给幼儿，因为疾病控制和预防中心周二晚上批准在儿童中使用该疫苗。在美国食品和药物管理局上周授权在临床试验之外使用疫苗后，该机构的认可是疫苗接种前的最后一步。9月份，许多高危成年人获得了疫苗加强注射的许可。</blockquote></p><p> Pfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world’s initial vaccine rollout, Mr. Bourla said in an interview.</p><p><blockquote>辉瑞计划明年生产约40亿剂，但已获得17亿剂的订单。布尔拉在接受采访时表示，订单数量表明它正在满足需求，低收入国家应该先于富裕国家达成供应协议，以避免像世界上最初推出疫苗那样落后。</blockquote></p><p> “We are already going way above what we forecast is needed based on the orders we have,” Mr. Bourla said. “If there are orders we will make more next year.”</p><p><blockquote>“根据我们现有的订单，我们的需求已经远远超出了我们的预测，”布尔拉先生说。“如果有订单，我们明年会生产更多。”</blockquote></p><p> While data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)表示，虽然辉瑞和其他研究人员的数据显示，额外剂量可能会增加保护作用，但研究第四剂疫苗的试验可能会在明年春天开始，大约在其研究中的试验对象接受第三剂疫苗一年后。在一次采访中。</blockquote></p><p> That could lead to study results in time for people to get a fourth dose when they get flu shots.</p><p><blockquote>这可能会让人们在注射流感疫苗时及时获得第四剂疫苗的研究结果。</blockquote></p><p> “It’s really to prepare for what we think is the very likely need for annual revaccinations,” he said.</p><p><blockquote>他说：“这实际上是为了为我们认为很可能需要每年重新接种疫苗的情况做好准备。”</blockquote></p><p> The company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.</p><p><blockquote>该公司最近表示，在一项大型研究中发现，第三剂疫苗是安全的，对有症状的Covid-19具有高度保护作用。</blockquote></p><p> The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.</p><p><blockquote>该疫苗130亿美元的收入是辉瑞第三季度约240亿美元销售额的最大贡献者，同比增长了一倍多。Bourla先生说，今年超过75%的疫苗销售额来自国际销售，因为疫苗已经到达152个国家。</blockquote></p><p> Pfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck& Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.</p><p><blockquote>辉瑞表示，预计其实验性Covid-19抗病毒药物的初步结果将于2022年第一季度末公布，该药物正处于后期测试阶段。研究人员正在接种疫苗和未接种疫苗的人以及低风险个体中研究该药物，这可能会将其与美国食品和药物管理局正在审查的默克公司和Ridgeback Biotherapeutics LP的一种有前途的抗病毒药物区分开来。</blockquote></p><p> The company has begun providing scientific data to the FDA, although it hasn’t formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.</p><p><blockquote>该公司已开始向FDA提供科学数据，尽管尚未正式请求授权。布尔拉说，如果获得授权，辉瑞公司今年将能够交付疫苗。</blockquote></p><p> Pfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.</p><p><blockquote>辉瑞生物制药总裁Angela Hwang表示，辉瑞预计全球多达1.5亿成年人可能因感染和密切接触而需要抗病毒药物。她说，长期销售和政府储存合同都有潜力。</blockquote></p><p> Pfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year’s revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.</p><p><blockquote>辉瑞预测，明年17亿剂的销售额将达到290亿美元，这反映了长期销售的持久性以及各国在冬季遏制病毒传播的努力。布尔拉先生说，许多国家将购买儿科剂量。明年的收入可能会更高，因为该预测反映了截至10月中旬签署的供应协议。</blockquote></p><p></p><p> Should the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world’s top-selling prescription drug in recent years has been AbbVie Inc.’s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.</p><p><blockquote>如果销售实现，他们将使辉瑞-BioNTech疫苗成为有史以来最畅销的药品。近年来全球最畅销的处方药是艾伯维公司（AbbVie Inc.）的抗炎药修美乐（Humira），2018年销售额近200亿美元。</blockquote></p><p> Pfizer splits vaccine sales with BioNTech.</p><p><blockquote>辉瑞与BioNTech分享疫苗销售。</blockquote></p><p> The outlook for Pfizer’s vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.</p><p><blockquote>辉瑞疫苗的前景反映了该疫苗相对于竞争对手疫苗的偏好。近2亿美国人已完全接种疫苗，其中一半以上接种了辉瑞-BioNTech疫苗。其余的大多数人接受了Moderna Inc.的疫苗，该疫苗使用类似的基于mRNA的技术。</blockquote></p><p> Pfizer has also distributed two billion doses so far and is on track to produce three billion doses.</p><p><blockquote>到目前为止，辉瑞公司也已经分发了20亿剂，并有望生产30亿剂。</blockquote></p><p> Mr. Bourla in the interview urged poor countries to secure supply—at discounted or not-for-profit prices—for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.</p><p><blockquote>布尔拉在采访中敦促贫穷国家确保明年的供应——以折扣或非盈利价格——他希望避免重蹈又一年落后于富裕国家的覆辙。他表示，希望世界卫生组织和Covax能够提供帮助。</blockquote></p><p> The Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.</p><p><blockquote>Covax计划由包括联合国儿童基金会和世卫组织在内的许多组织管理，旨在为富国和穷国提供公平获得疫苗的机会。</blockquote></p><p> Mr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.</p><p><blockquote>布尔拉表示，他已经致函各国，要求它们下订单，并表示它们应该比过去更加积极主动。</blockquote></p><p> “Some governments are better than others,” he said. “That’s the problem.”</p><p><blockquote>“有些政府比其他政府更好，”他说。“这就是问题所在。”</blockquote></p><p> Pfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.</p><p><blockquote>辉瑞和其他疫苗制造商因没有向中低收入国家提供足够的剂量而面临各国、公共卫生官员和药品获取倡导者的批评。一些国家缺乏与公司达成交易的资金或自行注射疫苗的知识，迫使它们依赖Covax计划。有供应协议的国家也因冷藏疫苗所需的基础设施不足而受到阻碍。</blockquote></p><p> Only 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.</p><p><blockquote>根据我们的世界数据，低收入国家只有3.7%的人至少接种了一剂Covid-19疫苗。一些批评者提议政府放弃知识产权以刺激生产，但这一想法遭到了疫苗制造商的拒绝。</blockquote></p><p> The Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.</p><p><blockquote>辉瑞-BioNTech疫苗预计很快将在美国提供给5岁以下的儿童，此前美国卫生当局上周授权其紧急使用，作为青少年的第一针Covid-19疫苗。该疫苗完全被批准用于16岁及以上的人，并被批准用于12岁及以上的儿童紧急使用。</blockquote></p><p> U.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.</p><p><blockquote>美国监管机构已批准为接种辉瑞-BioNTech疫苗的人在接种第二剂疫苗后至少六个月内接种加强剂，只要他们是老年人或因潜在疾病或工作场所而处于高风险。此后，监管机构将加强剂的可用性扩大到接受Moderna或强生的人。</blockquote></p><p> The Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.</p><p><blockquote>辉瑞-BioNTech疫苗通过临床试验和监管障碍的进展速度快于竞争对手批准用于成人的疫苗。</blockquote></p><p> Initial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.</p><p><blockquote>Dolsten博士说，辉瑞-BioNTech疫苗在2至4岁儿童中的临床研究的初步结果预计将于今年年底公布，而6个月至2岁以下儿童的数据将于下一季度末公布。</blockquote></p><p> Moderna said recently it won’t seek approval for its vaccine’s use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn’t started studying it yet in younger children.</p><p><blockquote>Moderna最近表示，在FDA批准青少年接种疫苗之前，它不会寻求批准其疫苗用于幼儿。强生公司是第三种获准在美国使用的疫苗，正在研究青少年的注射，但尚未开始在更小的儿童中研究。</blockquote></p><p> Pfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.</p><p><blockquote>辉瑞还上调了今年的整体财务指引，预计销售额为810亿美元至820亿美元，调整后每股收益为4.13美元至4.18美元。它将这一增长归因于疫苗和非疫苗的势头。</blockquote></p><p> Excluding the Covid-19 vaccine, sales of Pfizer’s other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.</p><p><blockquote>不包括Covid-19疫苗，辉瑞其他药物的销售额增长了7%。由于乳腺癌治疗药物Ibrance和前列腺癌药物Xtandi的销售额猛增，肿瘤药物销售额增长12%，达到超过30亿美元。血液稀释剂收入增长21%，超过13亿美元。</blockquote></p><p> Stripping out one-time items, the company’s adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.</p><p><blockquote>剔除一次性项目，该公司第三季度调整后利润为每股1.34美元。华尔街分析师此前预测营收为225.8亿美元，调整后每股收益为1.08美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-11-03 15:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales</p><p><blockquote>Shot 130亿美元的收入为制药商第三季度销售额做出了最大贡献</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/85ed5523396f63a03a4597730fa17ed8\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>Of the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.</span></p><p><blockquote><p class=\"t-img-caption\"><span>在近2亿已完全接种疫苗的美国人中，超过一半的人接种了辉瑞疫苗。</span></p></blockquote></p><p> Pfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.</p><p><blockquote>辉瑞公司(Pfizer Inc.)将今年Covid-19疫苗的销售额预测上调至约360亿美元，增幅约7%，正值美国准备向2800万5至11岁儿童分发疫苗之际。</blockquote></p><p> The New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.</p><p><blockquote>这家总部位于纽约的制药商表示，其与合作伙伴BioNTech SE开发的疫苗的销售预测考虑了今年预计交付约23亿剂疫苗。这些公司已经提高了生产剂量的能力，并正在与海外其他公司合作生产剂量。</blockquote></p><p> The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.</p><p><blockquote>该疫苗130亿美元的收入是辉瑞第三季度约240亿美元销售额的最大贡献者，同比增长了一倍多。辉瑞首席执行官Albert Bourla在财报看涨期权上表示，今年超过75%的疫苗销售额来自国际销售，因为该疫苗已到达152个国家。</blockquote></p><p> The vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.</p><p><blockquote>在接受初始供应的国家和其他已经开始加强运动的国家，以及尚未接受任何供应的国家，该疫苗在全球范围内仍然有需求。美国已授权为许多高危成年人额外注射该疫苗，并于上周批准将该疫苗用于5岁以下的儿童。</blockquote></p><p> In the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency’s endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.</p><p><blockquote>在美国，该疫苗预计最早将于周三在一些地方提供给幼儿，因为疾病控制和预防中心周二晚上批准在儿童中使用该疫苗。在美国食品和药物管理局上周授权在临床试验之外使用疫苗后，该机构的认可是疫苗接种前的最后一步。9月份，许多高危成年人获得了疫苗加强注射的许可。</blockquote></p><p> Pfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world’s initial vaccine rollout, Mr. Bourla said in an interview.</p><p><blockquote>辉瑞计划明年生产约40亿剂，但已获得17亿剂的订单。布尔拉在接受采访时表示，订单数量表明它正在满足需求，低收入国家应该先于富裕国家达成供应协议，以避免像世界上最初推出疫苗那样落后。</blockquote></p><p> “We are already going way above what we forecast is needed based on the orders we have,” Mr. Bourla said. “If there are orders we will make more next year.”</p><p><blockquote>“根据我们现有的订单，我们的需求已经远远超出了我们的预测，”布尔拉先生说。“如果有订单，我们明年会生产更多。”</blockquote></p><p> While data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)表示，虽然辉瑞和其他研究人员的数据显示，额外剂量可能会增加保护作用，但研究第四剂疫苗的试验可能会在明年春天开始，大约在其研究中的试验对象接受第三剂疫苗一年后。在一次采访中。</blockquote></p><p> That could lead to study results in time for people to get a fourth dose when they get flu shots.</p><p><blockquote>这可能会让人们在注射流感疫苗时及时获得第四剂疫苗的研究结果。</blockquote></p><p> “It’s really to prepare for what we think is the very likely need for annual revaccinations,” he said.</p><p><blockquote>他说：“这实际上是为了为我们认为很可能需要每年重新接种疫苗的情况做好准备。”</blockquote></p><p> The company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.</p><p><blockquote>该公司最近表示，在一项大型研究中发现，第三剂疫苗是安全的，对有症状的Covid-19具有高度保护作用。</blockquote></p><p> The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.</p><p><blockquote>该疫苗130亿美元的收入是辉瑞第三季度约240亿美元销售额的最大贡献者，同比增长了一倍多。Bourla先生说，今年超过75%的疫苗销售额来自国际销售，因为疫苗已经到达152个国家。</blockquote></p><p> Pfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck& Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.</p><p><blockquote>辉瑞表示，预计其实验性Covid-19抗病毒药物的初步结果将于2022年第一季度末公布，该药物正处于后期测试阶段。研究人员正在接种疫苗和未接种疫苗的人以及低风险个体中研究该药物，这可能会将其与美国食品和药物管理局正在审查的默克公司和Ridgeback Biotherapeutics LP的一种有前途的抗病毒药物区分开来。</blockquote></p><p> The company has begun providing scientific data to the FDA, although it hasn’t formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.</p><p><blockquote>该公司已开始向FDA提供科学数据，尽管尚未正式请求授权。布尔拉说，如果获得授权，辉瑞公司今年将能够交付疫苗。</blockquote></p><p> Pfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.</p><p><blockquote>辉瑞生物制药总裁Angela Hwang表示，辉瑞预计全球多达1.5亿成年人可能因感染和密切接触而需要抗病毒药物。她说，长期销售和政府储存合同都有潜力。</blockquote></p><p> Pfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year’s revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.</p><p><blockquote>辉瑞预测，明年17亿剂的销售额将达到290亿美元，这反映了长期销售的持久性以及各国在冬季遏制病毒传播的努力。布尔拉先生说，许多国家将购买儿科剂量。明年的收入可能会更高，因为该预测反映了截至10月中旬签署的供应协议。</blockquote></p><p></p><p> Should the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world’s top-selling prescription drug in recent years has been AbbVie Inc.’s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.</p><p><blockquote>如果销售实现，他们将使辉瑞-BioNTech疫苗成为有史以来最畅销的药品。近年来全球最畅销的处方药是艾伯维公司（AbbVie Inc.）的抗炎药修美乐（Humira），2018年销售额近200亿美元。</blockquote></p><p> Pfizer splits vaccine sales with BioNTech.</p><p><blockquote>辉瑞与BioNTech分享疫苗销售。</blockquote></p><p> The outlook for Pfizer’s vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.</p><p><blockquote>辉瑞疫苗的前景反映了该疫苗相对于竞争对手疫苗的偏好。近2亿美国人已完全接种疫苗，其中一半以上接种了辉瑞-BioNTech疫苗。其余的大多数人接受了Moderna Inc.的疫苗，该疫苗使用类似的基于mRNA的技术。</blockquote></p><p> Pfizer has also distributed two billion doses so far and is on track to produce three billion doses.</p><p><blockquote>到目前为止，辉瑞公司也已经分发了20亿剂，并有望生产30亿剂。</blockquote></p><p> Mr. Bourla in the interview urged poor countries to secure supply—at discounted or not-for-profit prices—for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.</p><p><blockquote>布尔拉在采访中敦促贫穷国家确保明年的供应——以折扣或非盈利价格——他希望避免重蹈又一年落后于富裕国家的覆辙。他表示，希望世界卫生组织和Covax能够提供帮助。</blockquote></p><p> The Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.</p><p><blockquote>Covax计划由包括联合国儿童基金会和世卫组织在内的许多组织管理，旨在为富国和穷国提供公平获得疫苗的机会。</blockquote></p><p> Mr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.</p><p><blockquote>布尔拉表示，他已经致函各国，要求它们下订单，并表示它们应该比过去更加积极主动。</blockquote></p><p> “Some governments are better than others,” he said. “That’s the problem.”</p><p><blockquote>“有些政府比其他政府更好，”他说。“这就是问题所在。”</blockquote></p><p> Pfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.</p><p><blockquote>辉瑞和其他疫苗制造商因没有向中低收入国家提供足够的剂量而面临各国、公共卫生官员和药品获取倡导者的批评。一些国家缺乏与公司达成交易的资金或自行注射疫苗的知识，迫使它们依赖Covax计划。有供应协议的国家也因冷藏疫苗所需的基础设施不足而受到阻碍。</blockquote></p><p> Only 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.</p><p><blockquote>根据我们的世界数据，低收入国家只有3.7%的人至少接种了一剂Covid-19疫苗。一些批评者提议政府放弃知识产权以刺激生产，但这一想法遭到了疫苗制造商的拒绝。</blockquote></p><p> The Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.</p><p><blockquote>辉瑞-BioNTech疫苗预计很快将在美国提供给5岁以下的儿童，此前美国卫生当局上周授权其紧急使用，作为青少年的第一针Covid-19疫苗。该疫苗完全被批准用于16岁及以上的人，并被批准用于12岁及以上的儿童紧急使用。</blockquote></p><p> U.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.</p><p><blockquote>美国监管机构已批准为接种辉瑞-BioNTech疫苗的人在接种第二剂疫苗后至少六个月内接种加强剂，只要他们是老年人或因潜在疾病或工作场所而处于高风险。此后，监管机构将加强剂的可用性扩大到接受Moderna或强生的人。</blockquote></p><p> The Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.</p><p><blockquote>辉瑞-BioNTech疫苗通过临床试验和监管障碍的进展速度快于竞争对手批准用于成人的疫苗。</blockquote></p><p> Initial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.</p><p><blockquote>Dolsten博士说，辉瑞-BioNTech疫苗在2至4岁儿童中的临床研究的初步结果预计将于今年年底公布，而6个月至2岁以下儿童的数据将于下一季度末公布。</blockquote></p><p> Moderna said recently it won’t seek approval for its vaccine’s use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn’t started studying it yet in younger children.</p><p><blockquote>Moderna最近表示，在FDA批准青少年接种疫苗之前，它不会寻求批准其疫苗用于幼儿。强生公司是第三种获准在美国使用的疫苗，正在研究青少年的注射，但尚未开始在更小的儿童中研究。</blockquote></p><p> Pfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.</p><p><blockquote>辉瑞还上调了今年的整体财务指引，预计销售额为810亿美元至820亿美元，调整后每股收益为4.13美元至4.18美元。它将这一增长归因于疫苗和非疫苗的势头。</blockquote></p><p> Excluding the Covid-19 vaccine, sales of Pfizer’s other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.</p><p><blockquote>不包括Covid-19疫苗，辉瑞其他药物的销售额增长了7%。由于乳腺癌治疗药物Ibrance和前列腺癌药物Xtandi的销售额猛增，肿瘤药物销售额增长12%，达到超过30亿美元。血液稀释剂收入增长21%，超过13亿美元。</blockquote></p><p> Stripping out one-time items, the company’s adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.</p><p><blockquote>剔除一次性项目，该公司第三季度调整后利润为每股1.34美元。华尔街分析师此前预测营收为225.8亿美元，调整后每股收益为1.08美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/pfizer-ups-covid-19-vaccine-forecast-as-sales-more-than-double-11635853492?mod=lead_feature_below_a_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/pfizer-ups-covid-19-vaccine-forecast-as-sales-more-than-double-11635853492?mod=lead_feature_below_a_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167449573","content_text":"Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales\nOf the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.\nPfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.\nThe New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.\nThe vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.\nThe vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.\nIn the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency’s endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.\nPfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world’s initial vaccine rollout, Mr. Bourla said in an interview.\n“We are already going way above what we forecast is needed based on the orders we have,” Mr. Bourla said. “If there are orders we will make more next year.”\nWhile data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.\nThat could lead to study results in time for people to get a fourth dose when they get flu shots.\n“It’s really to prepare for what we think is the very likely need for annual revaccinations,” he said.\nThe company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.\nThe vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.\nPfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck& Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.\nThe company has begun providing scientific data to the FDA, although it hasn’t formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.\nPfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.\nPfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year’s revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.\nShould the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world’s top-selling prescription drug in recent years has been AbbVie Inc.’s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.\nPfizer splits vaccine sales with BioNTech.\nThe outlook for Pfizer’s vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.\nPfizer has also distributed two billion doses so far and is on track to produce three billion doses.\nMr. Bourla in the interview urged poor countries to secure supply—at discounted or not-for-profit prices—for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.\nThe Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.\nMr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.\n“Some governments are better than others,” he said. “That’s the problem.”\nPfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.\nOnly 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.\nThe Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.\nU.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.\nThe Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.\nInitial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.\nModerna said recently it won’t seek approval for its vaccine’s use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn’t started studying it yet in younger children.\nPfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.\nExcluding the Covid-19 vaccine, sales of Pfizer’s other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.\nStripping out one-time items, the company’s adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":846,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":18,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/841538332"}
精彩评论